GEN Genetic Engineering & Biotechnology News (09.18.12)
Aids Weekly Plus
Mutabilis, the French biopharmaceutical company, has won a grant for €4 million (about US $5.3 million) in European Union (EU) Framework 7 funding as part of a collaborative project to develop new antiretroviral drugs to treat HIV. Mutabilis is coordinating the research. The purpose of the research is to develop a class of antiretrovirals that focuses on the interaction between the virus and host. Researchers involved in the work are the University College London; the Cancer Research Institute, United Kingdom; the Academic Medical Center of the University of Amsterdam; the AIDS Units Clinical Institute of the University of Barcelona; and researchers at the Institute Cochin, France, and the University Hematology Institute of the Saint Louis Hospital in Paris, France. The group can receive up to €6 million (about US $7.9 million) in funding over a three-year time frame.